🚀 FDA Approval Expected 2027-2028
Retatrutide: The Next Generation of GLP-1 Weight Loss
The most powerful weight loss drug in clinical trials. 24% average weight loss in 48 weeksbeating semaglutide and tirzepatide. Join the waitlist to be notified when it launches.
24%
Avg. Weight Loss
Phase 3
Clinical Trials
2027-28
Expected Launch
How Retatrutide Works
Retatrutide is a triple-agonist drug that activates three receptors: GLP-1, GIP, and glucagon. This combination delivers more weight loss than any FDA-approved medication.
🎯
Triple-Receptor Action
Targets GLP-1 (appetite), GIP (insulin), and glucagon (metabolism) for maximum fat burning.
📊
Proven in Trials
Phase 3 data shows 24% weight loss vs 22% for tirzepatidethe current gold standard.
💉
Once-Weekly Injection
Same convenience as Wegovy or Zepboundjust one subcutaneous injection per week.
🏥
Beyond Weight Loss
Also shows benefits for fatty liver (80% reduction), knee pain, and metabolic health.
*Pricing may vary. Requires medical consultation. We may earn a commission at no cost to you.